23 assets in Systemic Lupus Erythematosus

Therapeutic assets addressing Systemic Lupus Erythematosus, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Bcma-Cd19 Ccar T Cells Systemic Lupus Erythematosus	Peking University People's Hospital	P2	CCC (53)
Jnj-78436735 Systemic Lupus Erythematosus	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
Medroxyprogesterone Systemic Lupus Erythematosus	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
Moderna Covid-19 Vaccine Rna Systemic Lupus Erythematosus	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
Monovalent [B.1.351] Cov2 Pres Dtm-As03 Systemic Lupus Erythematosus	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
Methotrexate Systemic Lupus Erythematosus	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (52)
Cyclophosphamide Systemic Lupus Erythematosus	The Children's Hospital of Zhejiang University School of Medicine	P1	CCC (50)
Tozinameran Systemic Lupus Erythematosus	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (50)
Ucar T-Cell Systemic Lupus Erythematosus	The Children's Hospital of Zhejiang University School of Medicine	P1	CCC (50)
Naltrexone Systemic Lupus Erythematosus	Truway Health, Inc.	P1/2	CCC (48)
Autologous Cd19-Bcma Dual-Target Car T-Cell Therapy Systemic Lupus Erythematosus	Beijing Boren Hospital	P1	CC (43)
bnt162b2 Systemic Lupus Erythematosus	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CC (43)
Cabozantinib Systemic Lupus Erythematosus	National Cancer Institute (NCI)	P1	CC (43)
Gusacitinib Systemic Lupus Erythematosus	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	P1	CC (43)
hbi0101 cart Systemic Lupus Erythematosus	Polina Stepensky	P1	CC (43)
Ipilimumab Systemic Lupus Erythematosus	National Cancer Institute (NCI)	P1	CC (43)
Jwcar201 Systemic Lupus Erythematosus	RenJi Hospital	P1	CC (43)
Nivolumab Systemic Lupus Erythematosus	National Cancer Institute (NCI)	P1	CC (43)
her2bbζ/cd19t+ t cells Systemic Lupus Erythematosus	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	Early P1	C (39)
qt-219cx Systemic Lupus Erythematosus	The Children's Hospital of Zhejiang University School of Medicine	Early P1	C (39)
RD06-05 CART Cell Systemic Lupus Erythematosus	The Children's Hospital of Zhejiang University School of Medicine	Early P1	C (39)
Mtm-H-001 Systemic Lupus Erythematosus	Beijing GoBroad Hospital	N/A	D (30)
Lvivo-Tavec400 Product Systemic Lupus Erythematosus	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Early P1	NR ()